BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsCompany update

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing

Related news

CRSPCRISPR Therapeutics2026-10-19 20:05 EST

CRISPR Therapeutics Announces Chief Financial Officer Transition

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

NTLAIntellia2026-10-13 11:30 EST

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

SRPTSarepta Therapeutics2026-07-27 12:30 EST

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

NTLAIntellia2026-11-06 21:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-11-02 12:46 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-09-23 12:05 EST

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

ABEOAbeona Therapeutics2026-09-16 11:30 EST

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

EDITEditas Medicine2026-09-08 11:00 EST

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

SRPTSarepta Therapeutics2026-10-26 20:30 EST

Sarepta Therapeutics to Present at Upcoming Investor Conferences

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-11-02 13:00 EST

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

CRSPCRISPR Therapeutics2026-10-19 20:05 EST

CRISPR Therapeutics Announces Chief Financial Officer Transition

CRSPCRISPR Therapeutics2026-10-08 12:30 EST

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Stock data

Close
48.56 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States